PF-04691502

Alias: PF-04691502; PF 04691502; PF04691502; PF 4691502; PF4691502; PF-4691502
Cat No.:V0123 Purity: ≥98%
PF-04691502 is a novel, potent, ATP-competitive and selective dual inhibitor of PI3K (phosphatidylinositol 3 kinase) and mTOR (mammalian target of rapamycin) with potential anticancer activity.
PF-04691502 Chemical Structure CAS No.: 1013101-36-4
Product category: Akt
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1mg
5mg
10mg
25mg
50mg
100mg
250mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

PF-04691502 is a novel, potent, ATP-competitive and selective dual inhibitor of PI3K (phosphatidylinositol 3 kinase) and mTOR (mammalian target of rapamycin) with potential anticancer activity. With Ki of 1.8 nM, 2.1 nM, 1.6 nM, 1.9 nM, and 16 nM in cell-free assays, it inhibits PI3K(α/β/δ/γ)/mTOR. In terms of Vps34, AKT, PDK1, p70S6K, MEK, ERK, p38, or JNK, PF04691502 exhibits little activity. When cancer cells overexpress PI3K/mTOR, the potential anticancer drug PF-04691502 inhibits tumor growth.

Biological Activity I Assay Protocols (From Reference)
Targets
PI3Kδ (Ki = 1.6 nM); PI3Kα (Ki = 1.8 nM); PI3Kγ (Ki = 1.9 nM); PI3Kβ (Ki = 2.1 nM); mTOR (Ki = 16 nM)
ln Vitro
PF-04691502 inhibits recombinant class I PI3K and mTOR in biochemical assays and prevents the transformation of avian fibroblasts caused by wild-type PI3K γ, δ, or mutant PI3Kα. PF-04691502 inhibits cell proliferation (IC(50) of 179-313 nM) and lowers phosphorylation of AKT T308 and AKT S473 in PIK3CA-mutant and PTEN-deleted cancer cell lines, respectively. With an IC(50) of 32 nM, PF-04691502 inhibits the activity of mTORC1 in cells as determined by the PI3K-independent nutrient stimulated assay. It also prevents the activation of PI3K and mTOR downstream effectors such as AKT, FKHRL1, PRAS40, p70S6K, 4EBP1, and S6RP. While mTOR inhibition lasts for 24 to 48 hours after exposure to PF-04691502, short-term exposure primarily inhibits PI3K. In addition to upregulating p27 Kip1 and downregulating Rb, PF-04691502 causes cell cycle G(1) arrest. [1]
ln Vivo
In SKOV3 (PIK3CA mutation), U87 (PTEN null), and gefitinib- and erlotinib-resistant non-small cell lung carcinoma xenografts, antitumor activity of PF-04691502 is seen. [1] At 7 days, PF-04691502 reduces tumor growth by 72%. FDG-PET imaging demonstrated that PF-04691502 significantly lowers glucose metabolism. Following PF-04691502 treatment, p-AKT (S473) and p-RPS6 (S240/244), two tissue biomarkers of PI3K/mTOR pathway activity, are also severely inhibited. [2]
Enzyme Assay
The following procedure is used for the ATP competitive inhibition fluorescence polarization assay: mPI3Kα dilution solution (90 nM) is prepared in fresh assay buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 5 mM DTT, 0.05% CHAPS) and kept on ice. The enzyme reaction contains 0.5 nM mouse PI3Kα (p110α/p85α complex purified from insect cells), 30 μM PIP2, PF-04691502 (0, 1, 4, and 8 nM), 5 mM MgCl2, and 2-fold serial dilutions of ATP (0-800 μM). Dimethyl sulfoxide is 2.5% in the finished product. ATP is used to start the reaction, and 10 mM EDTA is used to stop it after 30 minutes. In a detection plate, 15 uL of the kinase reaction mixture is combined with 15 uL of the detector/probe mixture, which contains 480 nM GST-Grp1PH domain and 12 nM TAMRA-tagged fluorescent PIP3 in assay buffer. Before the plate is read on an LJL Analyst HT, it is shaken for 3 minutes and incubated for 35 to 40 minutes.
Cell Assay
In 96-well culture plates with growth medium containing 10% FBS, BT20, U87MG, and SKOV3 cells are seeded at a density of 3,000 cells per well. DMSO (0.1% final) or a compound that has been serially diluted is applied to cells after an overnight incubation period. 0.1 mg/mL receives resazurin addition. For three hours, plates are incubated in 5% CO2 at 37 °C. Following excitation at 530 nm, fluorescence signals are read as emission at 590 nm. Fluorescence intensity and drug concentration are plotted on a nonlinear curve to determine the IC50 values.
Animal Protocol
Mice: Female nu/nu mice (6-8 weeks old) are used. To prepare for implantation, tumor cells are removed and then re-suspended in matrigel (1:1) and serum-free medium. The region of the back flank is subcutaneously implanted with SKOV3, U87MG, or NSCLC cells (2.5-4 106). When a tumor's size ranges from 100 to 200 mm3, treatment can begin. The daily oral administration of PF-04691502 contains 0.5% methylcellulose in water suspension. Every two to three days, tumor volumes and animal body weights are measured. Vernier calipers are used to measure and calculate tumor volume. Calculated tumor growth inhibition (TGI) percentage. Data are shown as mean±SE.
References

[1]. Mol Cancer Ther. 2011 Nov;10(11):2189-99.

[2]. Mol Cancer Ther. 2011 Aug;10(8):1440-9.

[3]. Cancer Chemother Pharmacol. 2012 Aug;70(2):213-20.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C22H27N5O4
Molecular Weight
425.48
Exact Mass
425.2063
Elemental Analysis
C, 62.10; H, 6.40; N, 16.46; O, 15.04
CAS #
1013101-36-4
Appearance
Solid powder
SMILES
CC1=C2C=C(C(=O)N(C2=NC(=N1)N)C3CCC(CC3)OCCO)C4=CN=C(C=C4)OC
InChi Key
XDLYKKIQACFMJG-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H27N5O4/c1-13-17-11-18(14-3-8-19(30-2)24-12-14)21(29)27(20(17)26-22(23)25-13)15-4-6-16(7-5-15)31-10-9-28/h3,8,11-12,15-16,28H,4-7,9-10H2,1-2H3,(H2,23,25,26)
Chemical Name
2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
Synonyms
PF-04691502; PF 04691502; PF04691502; PF 4691502; PF4691502; PF-4691502
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~14 mg/mL (32.9 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.3503 mL 11.7514 mL 23.5029 mL
5 mM 0.4701 mL 2.3503 mL 4.7006 mL
10 mM 0.2350 mL 1.1751 mL 2.3503 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Status Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00445315 Completed Drug: PF-00868554
Drug: Placebo
Hepatitis C Pfizer January 2007 Phase 1
NCT01658176 Withdrawn Drug: PF-04691502
Drug: Exemestane
Breast Neoplasms Pfizer January 2013 Phase 2
Biological Data
  • PF-04691502

    Kinross KM, Mol Cancer Ther, 2011, 10(8), 1440-1449

  • PF-04691502
  • PF-04691502
Contact Us